

Philadelphia VFC Supplied Vaccines

As of February 03, 2011

Other (combination) vaccines are available; the chart below lists the vaccines only in their basic, generic components. Consult the current order form for all available products.

VACCINE	VFC COVERED CHILDREN	All or High Risk?
DT ¹	6 weeks through 6 years	See Footnote
DTaP	6 weeks through 6 years	All
Hepatitis A ²	12-23 months; 2-18 years	See Footnote
Hepatitis B	Birth through 18 years	All
Hib ³	6 weeks through 59 months	See Footnote
HPV ⁴	9 through 18 years	All
MMR ⁵	1 year through 18 years	See Footnote
Meningococcal Conjugate (MCV4) ⁶	10-18 years; 2-10 years	All; high-risk
Pneumococcal Conjugate (PCV13)	6 weeks through 59 months; 60-71 months	All; high-risk
Polio	6 weeks through 18 years	All
Tdap ⁷	7 years through 18 years	See Footnote
Td ⁸	7 years through 18 years	See Footnote
Varicella ⁵	1 year through 18 years	See Footnote
Pneumococcal Polysaccharide 23 (PPV23) ⁹	2 years through 18 years	See Footnote
Rotavirus	6 weeks to 32 weeks	All

- DT vaccine will be supplied for use in children with valid contraindications to pertussis antigen, as described by the ACIP. Please refer to the "Other" section of your VFC order form for DT requests.
- Hepatitis A vaccine is available for routine vaccination of all children 12-23 months of age, and for catch-up vaccination of all children 2-18 years of age who are unvaccinated for hepatitis A.
- Hib vaccine is available for unimmunized high-risk children ages 5 through 18 years, with either functional or anatomical asplenia (SSD, post-splenectomy); immunodeficiency; HIV infection; or immunosuppression due to HIV infection or chemotherapy.
- HPV Vaccine is available for routine vaccination at 11 through 12 years of age, for catch-up vaccination of children 13-18 years of age, and for children 9-11 years of age for whom protection is indicated. It is best to start the vaccine before the onset of sexual activity and exposure to HPV. Catch-up vaccination is recommended for individuals 13 - 18 years of age who haven't been vaccinated or not completed the full series.
Update: As of 12/2009, HPV4 may be given as a 3-dose series to **males 9-18 years** to reduce their likelihood of acquiring genital warts.
- Update:** -2/1/11 - MMRV is no longer available via the VFC program due to a supply shortage. MMR and Varicella are available as separate vaccines.
- Update:** 2/1/11 - The FDA expanded the indication for Menveo, Novartis to include children 2-10 years of age at high risk, coinciding with the age indication for only other U.S. licensed MCV4 vaccine, Menactra, by sanofi pasteur,
- Update:** 10/27/10 - Tdap can be administered regardless of the interval since the last tetanus- or diphtheria-toxoid containing vaccine. Children ages 7 through 10 years not fully vaccinated against pertussis and for whom no contraindication to pertussis vaccine exists should receive a single dose of Tdap. Adolescents ages 11 through 18 years who were never vaccinated against tetanus, diphtheria, or pertussis or who have unknown vaccination status should a single dose of Tdap. .
- Td vaccine will be supplied for use in children with valid contraindications to pertussis vaccine, as described by the ACIP, and for catch up for those children 7-18 years who have received a single dose of Tdap but must receive subsequent doses of a tetanus diphtheria containing vaccine. Please refer to the "Other" section of your VFC order form for Td requests.
- Pneumococcal Polysaccharide (23-valent) is available for children and adolescents aged 2-18 years who have functional or anatomical asplenia, immunocompromising illness or medications, chronic illness, who are Alaska Native or American Indian, or who have received a bone marrow transplant.